Kezar Life Sciences, Inc. announced that it has received clearance of its Investigational New Drug (IND) application from the FDA for zetomipzomib, its first-in-class, selective immunoproteasome inhibitor, for the treatment of autoimmune hepatitis.
[Kezar Life Sciences, Inc.]
